Citadel Advisors LLC grew its stake in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 219.8% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 22,133 shares of the company’s stock after buying an additional 15,213 shares during the period. Citadel Advisors LLC owned approximately 0.06% of Medpace worth $706,000 as of its most recent filing with the SEC.
Other large investors have also bought and sold shares of the company. Vanguard Group Inc. raised its position in Medpace by 23.3% in the second quarter. Vanguard Group Inc. now owns 1,014,439 shares of the company’s stock worth $29,419,000 after purchasing an additional 191,597 shares in the last quarter. Federated Investors Inc. PA raised its position in Medpace by 3.1% in the second quarter. Federated Investors Inc. PA now owns 184,469 shares of the company’s stock worth $5,350,000 after purchasing an additional 5,554 shares in the last quarter. Parametric Portfolio Associates LLC acquired a new position in Medpace in the second quarter worth about $325,000. American Century Companies Inc. acquired a new position in Medpace in the third quarter worth about $391,000. Finally, Northern Trust Corp raised its position in Medpace by 15.9% in the second quarter. Northern Trust Corp now owns 101,728 shares of the company’s stock worth $2,950,000 after purchasing an additional 13,938 shares in the last quarter. 16.80% of the stock is owned by hedge funds and other institutional investors.
In other Medpace news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of the company’s stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $30.16, for a total transaction of $138,736,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 25.80% of the stock is currently owned by corporate insiders.
Shares of Medpace Holdings Inc (NASDAQ:MEDP) traded up $0.88 during trading on Tuesday, reaching $37.14. 213,745 shares of the company’s stock traded hands, compared to its average volume of 167,850. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.68 and a quick ratio of 0.68. The company has a market capitalization of $1,362.69, a PE ratio of 54.62, a price-to-earnings-growth ratio of 1.86 and a beta of -1.04. Medpace Holdings Inc has a 1 year low of $21.76 and a 1 year high of $39.64.
Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, October 30th. The company reported $0.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.04. The firm had revenue of $98.68 million for the quarter, compared to analysts’ expectations of $96.84 million. Medpace had a net margin of 6.44% and a return on equity of 10.00%. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.40 earnings per share. equities analysts expect that Medpace Holdings Inc will post 1.5 EPS for the current fiscal year.
Several research firms recently issued reports on MEDP. Raymond James Financial began coverage on shares of Medpace in a research report on Friday, September 29th. They issued a “market perform” rating for the company. Jefferies Group increased their price target on shares of Medpace from $34.00 to $38.00 and gave the stock a “hold” rating in a research report on Wednesday, November 1st. William Blair lowered shares of Medpace from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 1st. They noted that the move was a valuation call. Robert W. Baird reissued a “hold” rating and issued a $32.00 price target on shares of Medpace in a research report on Monday, October 9th. Finally, BidaskClub raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Thursday, December 14th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $36.60.
WARNING: This article was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.truebluetribune.com/2018/01/03/medpace-holdings-inc-medp-shares-bought-by-citadel-advisors-llc-2.html.
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.